You just read:

Health Canada Approves XTANDI® (enzalutamide) - the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma Canada, Inc.

Jan 14, 2019, 08:00 ET